Navigation Links
Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
Date:2/13/2008

Review of VistaCare's first quarter operating results further convinces

Accipiter that Odyssey is acquiring VistaCare at a discount

NEW YORK, Feb. 13 /PRNewswire/ -- Accipiter Capital Management, the owner, together with its affiliates, of nearly 10% of the outstanding shares of common stock of VistaCare, Inc. (Nasdaq: VSTA), announced today that it had delivered a letter to VistaCare's Board of Directors stating that a review of VistaCare's Quarterly Report for the quarterly period ended December 31, 2007, has further convinced Accipiter that the offer by Odyssey Healthcare, Inc. (Nasdaq: ODSY) to acquire VistaCare for $8.60 per share is wholly inadequate. The letter further indicated that Accipiter was troubled by inconsistencies between VistaCare's internal analysis of the Company's restructuring and information VistaCare's management disclosed to investors. The letter calls on VistaCare's Board of Directors to explain these inconsistencies to stockholders and urges stockholders not to tender their shares in connection with the acquisition and to exercise their appraisal rights to the full extent permissible under law should the tender offer and subsequent merger be consummated.

Accipiter Capital Management and its affiliates do not intend to tender their shares in connection with the acquisition and plan to exercise their appraisal rights to the full extent permissible under law should the tender offer and subsequent merger be consummated. The text of the letter from Accipiter Capital Managem
'/>"/>

SOURCE Accipiter Capital Management
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Rural/Metro Board of Directors Meets With Accipiter Capital Management
2. Accipiter Capital Management Opposes Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. AtriCure to Present at Roth Capital Partners 2007 New York Conference
5. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
6. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
7. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
8. iCAD to Present at Americas Growth Capital 4th Annual Emerging Growth Conference
9. Pharsight Files Application for Nasdaq Capital Market Listing
10. Advanced Life Sciences Joins NASDAQ Capital Market
11. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 Biocides are chemical ... control bacteria or fungi growth and to prevent degradation ... the material and its surface. It is used in ... preservation, food and beverage, paints and coatings. It is ... sanitizers, as well as in industrial applications to prevent ...
(Date:7/29/2014)... Crohn,s and Colitis Canada has invested $3.4 million ... disease and ulcerative colitis, debilitating chronic diseases that ... grants will support 9 promising research projects across ... environmental causes of the diseases, improve our understanding ... to improve patient care and quality of life. ...
(Date:7/29/2014)... materials capable of repelling bacteria have each won ... to find out why. , Their bacteria ... in hospital infections acquired through implanted medical devices ... across the globe. , Morgan Alexander, Professor of ... Paul Williams, Professor of Molecular Microbiology, in the ...
(Date:7/29/2014)... the increasing use of electronic medical records and ... for a computerized version of the preventive care ... a new study, researchers from the Indiana University ... that substantial work lies ahead to convert the ... computerized prompts for physicians, but the payoff has ...
(Date:7/29/2014)... -- The U.S. should significantly reform the federal ... to ensure that the public,s $15 billion annual ... needs, says a new report by the Institute ... through Medicare -- requires little accountability, allocates funds ... offers insufficient opportunities to train physicians in the ...
Breaking Medicine News(10 mins):Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 2Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 3Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 4Health News:Prestigious Crohn's and Colitis Canada grants fund promising Canadian research 2Health News:Bacteria resistant materials -- £2m to get the 'inside' story 2Health News:Bacteria resistant materials -- £2m to get the 'inside' story 3Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 2Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 3Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 2Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 3
... Complex Rehab Market , , ... with 35 years of experience, has joined Alliance Seating ... complex rehab companies. O,Neill is an Assistive Technology Supplier ... and is responsible for sales and service of rehabilitation equipment ...
... 16 For the past 40 years, arc Thrift ... developmental,disabilities. This week, The Melvin and Elaine Wolf ... a Purpose" program. "As,one of the larger employers of ... partner with The Melvin and Elaine Wolf Foundation to ...
... a neurodegenerative disorder that causes the weakening of muscles, ... in 1 in 6,000 live births. While trans-splicing ... as a treatment for spinal muscular atrophy in cell-based ... the therapy to the human body. A University of ...
... The Journal of Nuclear Medicine SNM,s flagship publicationwill ... change to the publication allows the generous use of ... of research reports," said Heinrich R. Schelbert, M.D., editor ... . "Most important and critical, it strengthens the communication ...
... Mo. Evolving HIV viral strains and the adverse ... treatments propel scientists to continue exploring alternative HIV ... Missouri researcher has identified broad-spectrum aptamers. Aptamers are ... reproducing. In lab tests, aptamers known as RT5, ...
... autism are,struggling with a host of worries that impact ... their family will lack the life-long supports,needed to address ... released today by Easter Seals and made possible by ... Autism Study results reveal parents raising,children with autism are ...
Cached Medicine News:Health News:Veteran Rehab Specialist, Ted O'Neill, Joins Fast-Growing Alliance Seating & Mobility in Pennsylvania 2Health News:The Melvin and Elaine Wolf Foundation Donates $10,000 to arc Thrift Stores 2Health News:Journal of Nuclear Medicine premiers new, full-color design 2Health News:Researcher refining synthetic molecules to prevent HIV resistance 2Health News:Easter Seals' Study Sheds New Light on Parents' Life-Long Fears, Anxieties and Critical Supports Needed to Raise a Child With Autism 2Health News:Easter Seals' Study Sheds New Light on Parents' Life-Long Fears, Anxieties and Critical Supports Needed to Raise a Child With Autism 3Health News:Easter Seals' Study Sheds New Light on Parents' Life-Long Fears, Anxieties and Critical Supports Needed to Raise a Child With Autism 4Health News:Easter Seals' Study Sheds New Light on Parents' Life-Long Fears, Anxieties and Critical Supports Needed to Raise a Child With Autism 5Health News:Easter Seals' Study Sheds New Light on Parents' Life-Long Fears, Anxieties and Critical Supports Needed to Raise a Child With Autism 6
(Date:7/29/2014)...   , First patient ... efficacy and safety of MSB0010718C in patients with metastatic Merkel ... aggressive skin cancer lacking effective treatments   MSB0010718C is ... clinical trial for the treatment of solid tumors that aims ... a subsidiary of Merck KGaA, Darmstadt, Germany ...
(Date:7/28/2014)... , July 28, 2014  Dignity Health St. ... received the Get With The Guidelines®-Stroke Silver-Plus Quality ... outlined by the American Heart Association/American Stroke Association ... the number four cause of death and a ... the United States , according to the ...
(Date:7/28/2014)... , July 28, 2014 STAAR Surgical ... manufacturer and marketer of implantable lenses and delivery systems ... second quarter results and conference call with investors to ... 30, 2014.  The Company rescheduled the release date and ... funeral services for Hideo Watanabe , President of ...
Breaking Medicine Technology:EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3STAAR Surgical Moves Second Quarter Earnings Release and Conference Call One Day to July 31 2
... K-V Pharmaceutical Company ( KVa; KVb) (the "Company") ... HOLX ) that site initiation and patient enrollment has ... in the ongoing trial of Gestiva™ (hydroxyprogesterone caproate injection, 250 ... of preterm birth in women pregnant with a single baby ...
... The Wireless-Life Sciences Alliance (WLSA) , which convenes innovators, globally relevant ... in wireless technologies, today hailed its partner organizations for their collaboration and ... , , ... , , ...
Cached Medicine Technology:K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 2K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 3K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 4K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 5K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 6K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 7K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 8K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 9Wireless-Life Sciences Alliance (WLSA) Applauds Partner Organizations for Supporting Goal of Improving Healthcare Via Wireless Technologies 2Wireless-Life Sciences Alliance (WLSA) Applauds Partner Organizations for Supporting Goal of Improving Healthcare Via Wireless Technologies 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: